Being tested
B-cell depletion (anti-CD20): slow disability worsening in relapsing MS
relapsing MS · B-cell depletion (anti-CD20)
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 14
- Running now
- 3
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 53
Deciding trials (phase 2): 1 met, 0 did not.
Other linked trials: 13
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 2 · 2012 · Placebo-controlled · MSFT-NCT01569451
Other linked trials: 13
These linked trials do not set the status.
- AGNOSNo result found
Phase 4 · 2022 · Not randomised
- MOBILE-RMSOngoing
Phase 4 · 2021 · Not randomised
- Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabResult in a paper, not read yet
Phase 4 · 2020 · Not randomised
- STHENOSNo result found
Phase 3 · 2021 · Compared with dimethyl fumarate, diroximel fumarate, glatiramer acetate, interferon beta-1a, interferon beta-1b, peginterferon beta-1a, teriflunomide
- MUSETTEMissed main goal
Phase 3 · 2020 · Compared with ocrelizumab
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple SclerosisNo result found
Phase 3 · 2020 · Not randomised
- TG1101-RMS303Ongoing
Phase 3 · 2019 · Not randomised
- RIDOSE-MSNo result found
Phase 3 · 2018 · Compared with rituximab
- Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)Stopped: not working
Phase 3 · 2017 · Not randomised
- CASTINGNo result found
Phase 3 · 2016 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 13 → 14
- 2026-10-27First listed as Being tested
Related hypotheses
- B-cell depletion (anti-CD20): slow disability worsening in NMOSD
- B-cell depletion (anti-CD20): slow disability worsening in primary progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in relapsing and progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in secondary progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error